Dectrocel develops AI-powered diagnostic tools, with flagship product DecXpert delivering chest X-ray and CT-scan interpretations and claiming 10x faster results with 98% accuracy. DecXpert is one of only three AI-based diagnostic tools approved for clinical use in India by the CDSCO and reports a 40.1% improvement in missed case detection validated in Nature Scientific. The company targets diagnostic gaps caused by India’s acute radiologist shortage (reported 1:125,000), particularly in tier-2 and smaller cities where delays and errors are common. Dectrocel plans to scale commercial deployment across OEM partner networks, penetrate India’s digital X-ray market, and establish an initial presence in Southeast Asia. It is also developing new diagnostic modules for CT/MRI/PET-CT and HPB disease detection and enhancing its self-learning multimodal AI capabilities. The company raised Rs 4 crore in the reported funding round to support these plans.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2025